InvestorsHub Logo
Followers 4
Posts 1242
Boards Moderated 0
Alias Born 01/16/2016

Re: Bobby Marinov post# 4868

Friday, 01/19/2018 2:27:38 AM

Friday, January 19, 2018 2:27:38 AM

Post# of 6602
Cybathlon is totally irrelevant for EKSO.

Being able to walk quickly DOES NOT MAKE A SIGNIFICANT DIFFERENCE at this stage in rehabilitation for exoskeletons.

Rehabilitation and ambulation are largely separate goals.

What does matter to Ekso is how much their patients gaits improve after getting out of the exoskeleton. The primary factor determining this has to do with how much user imput there is. Ekso's SmartAssist blows the competition out of the water in this regard. The second major factor is going to be Functional Electronic Stimulation (FES). Another place Ekso has a big lead on almost all other exoskeletons.

Remember an Ekso paired with FES resulted in this:

newsroom.ucla.edu/releases/completely-paralyzed-man-voluntarily-moves-his-legs-ucla-scientists-report

To be fair, simply having an exoskeleton do most of the work, reading where the person wants to go, and doing it quickly is of some value. It's just not what Ekso's products are designed to do currently. When ambulation does come to be a primary goal of Ekso, I expect them to enter the Cybathlon
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EKSO News